Part 1: Targeted Therapy for NSCLC: Toxicity Profile of ADCs

2 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Targeted Therapy for NSCLC: Toxicity Profile of ADCs, is part 1 of the 3-part series, Target Therapy for NSCLC: Targeted Drug Conjugates.

SERIES CONTENT
1) Targeted Therapy for NSCLC: Toxicity Profile of ADCs
2) ADCs Targeting TROP2 in NSCLC: Overview and Recent Data
3) ADCs for NSCLC: HER2 and HER3

LEARNING OBJECTIVES
Upon completion of this series, participants should be better able to:
-Address barriers to awareness, preparedness, adoption, and potential of ADCs for the treatment of NSCLC
-Understand recent clinical evidence for the use of ADC monotherapy versus combination approaches with other immunotherapies
-Improve coordination and communication within the multidisciplinary cancer care team to optimize outcomes for patients with NSCLC being treated with ADCs
-Review patient selection principles and implications of treatment selection for future therapeutic options in NSCLC.

For additional lung cancer resources please visit the accc-cancer.org/lung-cancer page.

SPEAKERS
Benjamin P. Levy, MD Clinical Director of Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Beth Sandy, CRNP Thoracic Oncology Nurse Practitioner, Abramson Cancer Center, University of Pennsylvania
Alexander Spira MD, PhD, FACP, FASCO Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program, Clinical Assistant Professor, Johns Hopkins School of Medicine
Category
Oncology
Be the first to comment

Up Next